News from regeneron pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 29, 2015, 09:30 ET

Regeneron Announces Upcoming 2015 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Bank of...

Apr 10, 2015, 09:30 ET

Regeneron to Report First Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on May 7, 2015

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2015 financial and operating results on...

Mar 25, 2015, 11:02 ET

EYLEA® (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Retinopathy in Patients with Diabetic Macular Edema (DME)

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA®...

Mar 15, 2015, 11:00 ET

Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that 18-month (78-week) results of a Phase 3 trial of Praluent™...

Mar 15, 2015, 11:00 ET
Sanofi logo

Sanofi and Regeneron Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

 Sanofi and Regeneron Pharmaceuticals, Inc. today announced that 18-month (78-week) results of a Phase 3 trial of Praluent™ (alirocumab),...

Feb 26, 2015, 08:40 ET

EYLEA® (aflibercept) Injection Receives EU Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Retinal Vein Occlusion

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European...

Feb 18, 2015, 17:00 ET

NIH-Sponsored Comparative Effectiveness Trial in Diabetic Macular Edema Shows EYLEA® (aflibercept) Injection Demonstrated Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that results from the National Institutes of Health (NIH)-sponsored, Diabetic...

Feb 18, 2015, 08:00 ET
View Interactive Maps on www.CholesterolCounts.com for a Snapshot of Cholesterol Awareness Across the U.S.

New Results from Cholesterol Counts Show Most Americans Polled Do Not Know Their Bad Cholesterol (LDL-C) Levels

Despite the fact that high LDL-C (bad cholesterol) is a critical heart health factor for adults,1 71 percent of Americans surveyed (n=2,033) are...

Feb 13, 2015, 09:30 ET

Regeneron Announces Upcoming 2015 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - 2015 RBC...

Feb 10, 2015, 06:30 ET

Regeneron Reports Fourth Quarter and Full Year 2014 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2014 and provided an...

Jan 26, 2015, 01:00 ET

Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Jan 23, 2015, 07:32 ET

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by...

Jan 12, 2015, 01:00 ET

Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

 Regeneron (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review the Marketing...

Jan 09, 2015, 09:30 ET

Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2014 financial and...

Jan 09, 2015, 01:00 ET

Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess...

Dec 19, 2014, 09:30 ET

Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the 33rd Annual J.P. Morgan Healthcare Conference...

Dec 15, 2014, 08:00 ET
Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol

Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating with nationally-recognized...

Dec 01, 2014, 07:00 ET

EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

Nov 20, 2014, 01:30 ET

Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted...

Nov 19, 2014, 08:15 ET

Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials that...